Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia Corp Chief Commercial Officer Moomaw Scott exercised stock options and sold shares in a planned liquidity move. He exercised options covering a total of 80,000 shares of common stock at exercise prices of $2.54, $2.97, and $3.40 per share, converting them into common shares.
On the same date, he sold 80,000 shares of common stock at a volume-weighted average price of $35.3228 per share, with individual trade prices ranging from $35.01 to $35.75. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating the transactions were scheduled in advance.
Following these transactions, Moomaw Scott directly owns 188,954 shares of Liquidia common stock and also holds multiple unvested restricted stock units that continue to tie part of his compensation to the company’s future share performance.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice reporting sales and planned transfers of Common stock related to employee plans and option exercises. The filing lists planned transfers of 97,000 shares by exercise on 03/09/2026, 1,314 shares from the Employee Stock Purchase Plan (as of 08/31/2024), and 1,686 restricted stock units (as of 04/11/2025.
The filing also reports recent open-market dispositions by Scott Moomaw: 827 shares sold on 03/02/2026 for $25,289.66 and 20,533 shares sold on 01/12/2026 for $768,550.19.
Liquidia Corporation filed a shelf registration on Form S-3 to permit the sale, "from time to time after the effective date," of common stock, preferred stock, debt securities, warrants and units. The prospectus describes primary offerings sold in one or more transactions and states that specific terms will be provided in prospectus supplements.
The prospectus notes the company’s commercialization of YUTREPIA and ongoing collaboration with Sandoz, and discloses pending litigation with United Therapeutics that seeks remedies including removal of YUTREPIA from the market. The company’s common stock last reported sale price was $34.38 per share on March 4, 2026.
Liquidia Corporation outlines its strategy as a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company markets YUTREPIA, an FDA-approved dry-powder treprostinil inhalation launched in June 2025, designed for deep-lung delivery and higher titratable doses via a low‑effort inhaler.
Liquidia also shares profits from U.S. sales of Treprostinil Injection, a fully substitutable generic version of Remodulin, through an exclusive promotion agreement with Sandoz. Its pipeline includes L606, a twice‑daily, sustained‑release liposomal treprostinil delivered by next‑generation nebulizers, now in an open‑label PAH/PH‑ILD study and a global pivotal PH‑ILD trial.
The report emphasizes the proprietary PRINT particle engineering platform, an expanding patent estate protecting YUTREPIA into 2037, key licenses with Pharmosa, Vectura, UNC and GSK, and a concentrated commercial focus on U.S. PAH and PH‑ILD centers. As of June 30, 2025, non‑affiliate market value was $847.0 million, and 88,114,429 common shares were outstanding as of February 17, 2026.
Liquidia Corporation reported a transformative 2025 driven by the U.S. launch of YUTREPIA. Product sales, net, reached $148.3 million for the year, contributing to total revenue of $158.3 million compared with $14.0 million in 2024. In fourth quarter 2025 the company generated net income of $14.6 million and non-GAAP adjusted EBITDA of $27.3 million, marking a second consecutive profitable quarter.
For full year 2025, Liquidia recorded a net loss of $68.9 million, an improvement from a $128.3 million loss in 2024. Cash and cash equivalents were $190.7 million as of December 31, 2025, up from $176.5 million a year earlier, while total assets increased to $327.9 million. Research and development expenses fell 18% to $39.3 million, as efforts shifted toward commercialization, while selling, general and administrative expenses nearly doubled to $157.2 million to support the YUTREPIA launch and related legal costs.
Liquidia Corp’s General Counsel Russell Schundler reported several equity transactions. He sold 1,073 shares of common stock in an open‑market trade at $30.58 per share, executed under a Rule 10b5‑1 trading plan and described as covering taxes from previously granted restricted stock units (RSUs). He also exercised 2,344 RSUs, which converted into an equal number of common shares at no cost, increasing his directly held common stock to 614,057 shares. Separately, 14,500 common shares are reported as held indirectly by his spouse, with beneficial ownership disclaimed except to the extent of his pecuniary interest. Footnotes detail multiple prior RSU grants and unvested awards that are included in his overall equity position.
Liquidia Corp Chief Commercial Officer Scott Moomaw reported a mix of RSU activity and a small share sale. On March 2, 2026, he completed an open-market sale of 827 shares of common stock at $30.58 per share under a pre-arranged Rule 10b5-1 trading plan. The filing notes these shares were sold to cover taxes from the settlement of restricted stock units originally granted on January 16, 2022. On February 27, 2026, RSUs converted into 1,875 shares of common stock on a one-for-one basis at a stated price of $0.00 per share, reflecting an exercise or conversion of derivative securities. After these transactions, Moomaw directly owned 188,954 shares of common stock, alongside additional unvested RSUs described in the footnotes.
Liquidia Corp executive Sarah Krepp, the company’s Chief Human Resource Officer, reported an open-market sale of 276 shares of common stock at $30.58 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on December 15, 2023.
According to the filing, these shares were sold to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024. After this sale, Krepp directly holds 164,658 shares of common stock, including multiple blocks of unvested RSUs granted between January 2024 and January 2026 and 5,749 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corp executive Michael Kaseta, the CFO and COO, reported a mix of stock sales and equity awards. He sold 1,165 shares of common stock in an open-market transaction at $30.58 per share under a pre-arranged Rule 10b5-1 trading plan to cover taxes tied to restricted stock units (RSUs) granted in January 2022. After this sale, he directly owned 411,855 common shares. On February 27, 2026, 2,344 RSUs converted into 2,344 common shares at no cost, reflecting the vesting and settlement of a portion of his long-term equity awards.
Liquidia Corp Chief Accounting Officer Dana Boyle reported an open-market sale of 445 shares of common stock at $30.58 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 3, 2022, and was made to cover taxes tied to the settlement of previously granted restricted stock units. After this transaction, Boyle directly holds 178,840 shares of Liquidia common stock, which includes multiple unvested RSU awards and shares acquired through the company’s employee stock purchase plan.